Clinical Trial Update: A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and efficacy of PRT060128, a P2Y12 inhibitor, in non-urgent PCI; trial completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Percutaneous Coronary Intervention

Drugs mentioned

• PRT060128 (PRT060128)

Snippet

Sponsor: Portola Pharmaceuticals | Conditions: Percutaneous Coronary Intervention | Phase 2 | Status: COMPLETED